Trial Profile
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary) ; Adalimumab
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT - PsA 1
- Sponsors AbbVie; AbbVie Germany
- 15 Nov 2023 Results (n=1281) assessing the direct and indirect effects of treatment with upadacitinib or adalimumab vs placebo on pain in patients with PsA presented at the ACR Convergence 2023
- 15 Nov 2023 Results of post hoc analysis assessing the achievement of goals according to these measures in pts with PsA following long-term treatment with upadacitinib (UPA), an oral JAK inhibitor, at week (wk) 152 from two phase 3 trials(SELECT-PsA 1 and SELECT-PsA 2), presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of post hoc analysis evaluating long-term efficacy of UPA in patients with PsA and involvement in 1 or more regions of weight-bearing joints from SELECT-PsA 1 and SELECT-PsA 2 trials, presented at the ACR Convergence 2023.